Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. lessened its holdings in Veracyte, Inc. (NASDAQ:VCYTGet Rating) by 15.8% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 20,813 shares of the biotechnology company’s stock after selling 3,910 shares during the period. Advisors Asset Management Inc.’s holdings in Veracyte were worth $414,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Point72 Hong Kong Ltd acquired a new position in Veracyte in the 1st quarter worth approximately $33,000. Assetmark Inc. grew its stake in shares of Veracyte by 90.3% during the 2nd quarter. Assetmark Inc. now owns 2,596 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 1,232 shares during the period. First Horizon Advisors Inc. grew its stake in shares of Veracyte by 16,813.6% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,721 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 3,699 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Veracyte during the 1st quarter worth approximately $73,000. Finally, Lazard Asset Management LLC grew its stake in shares of Veracyte by 46.3% during the 1st quarter. Lazard Asset Management LLC now owns 3,410 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 1,079 shares during the period.

Insider Buying and Selling at Veracyte

In other Veracyte news, Director Evan/ Fa Jones sold 6,000 shares of the firm’s stock in a transaction on Friday, November 11th. The stock was sold at an average price of $30.23, for a total value of $181,380.00. Following the transaction, the director now owns 52,451 shares in the company, valued at approximately $1,585,593.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Veracyte news, insider Giulia C. Kennedy sold 1,023 shares of the firm’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $25.00, for a total value of $25,575.00. Following the transaction, the insider now owns 68,001 shares in the company, valued at approximately $1,700,025. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Evan/ Fa Jones sold 6,000 shares of the firm’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of $30.23, for a total value of $181,380.00. Following the completion of the transaction, the director now owns 52,451 shares in the company, valued at approximately $1,585,593.73. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,025 shares of company stock worth $207,014. Corporate insiders own 2.90% of the company’s stock.

Veracyte Price Performance

Shares of NASDAQ:VCYT opened at $25.98 on Friday. The business’s 50 day moving average price is $19.74 and its 200-day moving average price is $20.67. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of -43.30 and a beta of 1.28. Veracyte, Inc. has a 1 year low of $14.85 and a 1 year high of $49.80.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on VCYT. StockNews.com raised shares of Veracyte from a “sell” rating to a “hold” rating in a research note on Friday, November 11th. Morgan Stanley dropped their price objective on shares of Veracyte from $23.00 to $22.00 and set an “underweight” rating on the stock in a research note on Friday, November 4th. SVB Leerink raised their price objective on shares of Veracyte from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, November 3rd. Needham & Company LLC increased their target price on Veracyte from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 3rd. Finally, Raymond James decreased their target price on Veracyte from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Friday, November 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Veracyte has an average rating of “Moderate Buy” and an average price target of $35.17.

Veracyte Company Profile

(Get Rating)

Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.

Featured Articles

Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYTGet Rating).

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.